The role of immunoprophylaxis in the reduction of disease attributable to respiratory syncytial virus.
H Cody Meissner, Joseph A Bocchini, Michael T Brady, Caroline B Hall, David W Kimberlin, Larry K Pickering
Author Information
- H Cody Meissner: Division of Pediatric Infectious Disease, Tufts Medical Center, Boston, Massachusetts 02111, USA. cmeissner@tuftsmedicalcenter.org
No abstract text available.
Antibodies, Monoclonal
Antibodies, Monoclonal, Humanized
Antiviral Agents
Child
Child, Preschool
Cost-Benefit Analysis
Cross-Sectional Studies
Evidence-Based Medicine
Health Care Costs
Humans
Infant
Infant, Newborn
Infant, Premature, Diseases
Palivizumab
Population Surveillance
Practice Guidelines as Topic
Respiratory Syncytial Virus Infections
Respiratory Syncytial Viruses
Risk Factors
United States
Antibodies, Monoclonal
Antibodies, Monoclonal, Humanized
Antiviral Agents
Palivizumab
